Review on lipegfilgrastim
Maja Gasparic, Sophie LeymanTeva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the NetherlandsHaving read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of lipegfilgrastim to be entirely accurate, and we...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/71f97796db5a4d8f91a8d2a32e5ba85e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Maja Gasparic, Sophie LeymanTeva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the NetherlandsHaving read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of lipegfilgrastim to be entirely accurate, and we would therefore like to clarify what lipegfilgrastim actually is.The description of lipegfilgrastim used in the original article was a “long-acting biosimilar filgrastim”.1 This description was subsequently amended in the corrigendum to “lipegfilgrastim has an active substance that is similar to filgrastim, with similar pharmacokinetics, receptor binding affinity, safety and efficacy as pegfilgrastim”.2 Read the Corrigendum |
|---|